cholestasis

Undiagnosed TB deaths in England highlight diagnostic failures

Hundreds of individuals in England have died from tuberculosis without receiving a diagnosis, underscoring critical gaps in public health surveillance and clinical detection pathways.

Milvexian fails to cut ischemic risk in recent ACS, raising questions for FXIa inhibitors

Milvexian did not reduce ischemic events in patients with recent acute coronary syndrome, despite its mechanism as a factor XIa inhibitor.

ICD-11: What European GPs need to know about the new classification system

The ICD-11 system introduces significant changes to disease classification, impacting coding for conditions like hidradenitis suppurativa and neonatal encephalopathy.

Biomarkers predict early rhythm control benefit in AFib

Early rhythm control's benefit in atrial fibrillation varies by baseline biomarker levels, with higher NT-proBNP and hs-cTnT indicating greater risk reduction.

Serology and PCR: Optimising COVID-19 Episode Identification

Integrating serology with PCR and rapid antigen tests improves COVID-19 episode identification, particularly in vaccinated individuals, according to BRACE trial insights.

Navigating Dilated Cardiomyopathy: Beyond Standard Care

Dilated cardiomyopathy management focuses on symptom control, preventing disease progression, and reducing adverse cardiac events through guideline-directed medical therapy.

Noninvasive Ventilation: A Shift in End-of-Life Care for ALS?

Noninvasive ventilation may reduce requests for medical assistance in dying (MAiD) among patients with amyotrophic lateral sclerosis (ALS). This suggests a potential impact on end-of-life decisions.

Traditional Chinese Medicines Plus Metformin: An A1c Advantage?

Combining Traditional Chinese Medicines with metformin may offer additional A1c reductions for patients with type 2 diabetes.

Atorvastatin's CV Benefit in Older Adults: More Nonfatal Events Than Deaths?

Atorvastatin reduces major cardiovascular events in older adults, with the benefit primarily driven by a reduction in nonfatal events rather than mortality.